Systemic complications of nonsteroidal anti-inflammatory drug use

Advances in Internal Medicine

Volumn 41, Issue , 1996, Pages 605-639

  Palmer, Biff F ^a   Henrich, William L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN;

BIOSYNTHESIS; DIGESTIVE SYSTEM; DRUG EFFECT; HUMAN; KIDNEY; METABOLISM; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIGESTIVE SYSTEM; HUMANS; KIDNEY; PROSTAGLANDINS;

EID: 0030344852     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (153)

1. Smith WL: Prostanoid biosynthesis and mechanisms of action. Am / PhysioJ 263:F181-F191, 1992.
2. Schlondorff D: Renal prostaglandin synthesis: Sites of production and specific actions of prostaglandins. Am / Med 81(suppl 2B):1-11, 1986.
3. Uchida S, Nonoguchi H, Endou H: Localization and properties of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase activity in the rat kidney. Pflugers Arch 404:278-284, 1985.
4. Stein JH, Fadem SZ: The renal circulation. JAMA 239:1308-1311, 1978.
5. Kirschenbaum MA, White N, Stein JH, et al: Redistribution of renal cortical blood flow during inhibition of prostaglandin synthesis. Am J Physiol 227:801-805, 1974.
6. Edwards RM: Effects of prostaglandins on vasoconstrictor action in isolated renal arterioles. Am J Physiol 248:F779-F784,1985.
7. Arima S, Ren Y, Juncos LA, et al: Glomerular prostaglandins modulate vascular reactivity of the downstream efferent arterioles. Kidney Int 45:650-658, 1994.
8. Scharschmidt L, Simonson M, Dünn MJ: Glomerular prostaglandins, angiotensin II, and nonsteroidal anti-inflammatory drugs. Am J Med 81(suppl 2B):30-42, 1986.
9. Uchida K, Ballermann BJ: Sustained activation of PGE2 synthesis in mesangial cells cocultured with glomerular endothelial cells. Am J Physiol 263:C200-C209, 1992.
10. Schlondorff D, Aynedjian HS, Satriano JA, et al: In vivo demonstration of glomerular PGE2 responses to physiological manipulations and experimental agents. Am J Physio! 252:F717-F723, 1987.
11. Henrich WL, Anderson RJ, Berns AS, et al: The role of renal nerves and prostaglandins in control of renal hemodynamics and plasma renin activity during hypotensive hemorrhage in the dog. J Clin Invest 61:744-750, 1978.
12. Henrich WL, Berl T, McDonald KM, et al: Angiotensin II, renal nerves, and prostaglandins in renal hemodynamics during hemorrhage. Am / Physiol 235:F46-F51, 1978.
13. Muther RS, Potter DM, Bennett WM: Aspirin-induced depression of glomerular filtration rate in normal humans: Role of sodium balance. Ann Intern Med 94:317-321, 1981.
14. Kramer HJ, Stinnesbeck B, Klautke G, et al: Interaction of renal prostaglandins with the renin-angiotensin and renal adrenergic nervous systems in healthy subjects during dietary changes in sodium intake. Clin Sei 68:387-393, 1985.
15. Cannon PJ: Prostaglandins in congestive heart failure and the effects of nonsteroidal anti-inflammatory drugs. Ann J Med 81(suppl 2B):123-132, 1986.
16. Zipser RD: Role of renal prostaglandins and the effects of nonsteroidal anti-inflammatory drugs in patients with liver disease. Am J Med 81(suppl 2B):95-103, 1986.
17. Gentilini P: Cirrhosis, renal function and NSAIDs. J Hepatol 19:200203, 1993.
18. Kleinknecht C, Broyer M, Gubler M-C, et al: Irreversible renal failure after indomethacin in steroid-resistant nephrosis. N Engl J Med 302:691, 1980.
19. ter Wee PM, Donker AJM: Pharmacologie manipulation of glomerular function. Kidney Int 45:417-424, 1994.
20. Henrich WL, Hamasaki Y, Said S, et al: Dissociation of systemic and renal effects in endotoxemia. / Clin Invest 69:691-699, 1982.
21. Favre L, Glasson P, Vallotton MB: Reversible acute renal failure from combined triamterene and indomethacin. Ann Intern Med 96:317-320, 1982.
22. Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal antiinflammatory drugs. N EngJ / Med 310:563-572, 1984.
23. Nath KA, Chmielewski DH, Hostetter TH: Regulatory role of prostanoids in glomerular microcirculation of remnant nephrons. Am / PhysioJ 252:F829-F837, 1987.
24. Patrono C, Pierucci A: Renal effects of nonsteroidal anti-inflammatory drugs in chronic glomerular disease. Am / Med 81(suppl 2B):71-83, 1986.
25. Takahashi K, Schreiner GF, Yamashita K, et al: Predominant functional roles for thromboxane A2 and prostaglandin E2 during late nephrotoxic serum glomerulonephritis in the rat. / Clin Invest 85:1974-1982, 1990.
26. Yanagisawa H, Jim Z, Kurihara N, et al: Increases in glomerular eicosanoid production in rats with bilateral ureteral obstruction are mediated by enhanced enzyme activities of both the cyclooxygenase and 5-lipooxygenase pathways. Proc Soc Exp Biol Med 203:291-296, 1993.
27. Cantley LG, Spokes K, Clark B, et al: Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int 44:1217-1223, 1993.
28. Altman RD, Ferez GO, Sfakianakis GN: Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis. Am J Med 93:396-402, 1992.
29. Murray MD, Brater DC, Tierney WM, et al: Ibuprofen-associated renal impairment in a large general internal medicine practice. Am J Med Sei 299:222-229, 1990.
30. Gurwitz JH, Avorn J, Ross-Degnan D, et al: Nonsteroidal antiinflammatory drug-associated azotemia in the very old. JAMA 264:471-475, 1990.
31. Palmer BF, Levi M: Effect of aging on renal function and disease, in Brenner BM, Rector FC (eds): The Kidney, ed 5. Philadelphia, WB Saunders, 1995, in press.
32. Schlondorff T: Renal complications of nonsteroidal anti-inflammatory drugs. Kidney IntJ 44:643-653, 1993.
33. Bennett WM: Geriatric pharmacokinetics and the kidney. Am / Kidney Dis 16:283-288, 1990.
34. Stillman MT, Schlesinger PA: Nonsteroidal anti-inflammatory drug nephrotoxicity. Arch Intern Med 150:268-270, 1990.
35. Abraham PA, Stillman MT: Salsalate exacerbation of chronic renal insufficiency. Arch Intern Med 147:1674-1676, 1987.
36. Bunning RD, Barth WF: Sulindac: A potentially renal-sparing nonsteroidal anti-inflammatory drug. JAMA 248:2864-2867, 1982.
37. Ciabattoni G, Cinotti GA, Pierucci A, et al: Effects of sulindac and ibuprofen in patients with chronic glomerular disease. N Engl J Med 310:279-283, 1984.
38. Eriksson L-O, Sturfeit G, Thysell H, et al: Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med 89:313-321, 1990.
39. Eriksson L-O, Beermann B, Kallner M: Renal function and tubular transport effects of sulindac and naproxen in chronic heart failure. Clin Pharmacol Ther 42:646-654, 1987.
40. Laffi G, Daskolopoulos G, Kronborg I, et al: Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. Gastroenterology 90:182-187, 1986.
41. Miller MJS, Bednar MM, McGiff JC: Renal metabolism of sulindac: Functional implications. J PharmacoJ Exp Ther 231:449-456, 1984.
42. Whelton A, Stout RL, Spilman PS, et al: Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. Ann Intern Med 112:568-576, 1990.
43. Klassen DK, Stout RL, Silman PS, et al: Sulindac kinetics and effects on renal function and prostaglandin excretion in renal insufficiency. / Clin Pharmacol 29:1037-1042, 1989.
44. Quintero E, Gines P, Arroyo V, et al: Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites. Nephron 42:298-303, 1986.
45. Brater DC, Anderson S, Baird B, et al: Effects of ibuprofen, naproxen, and sulindac on prostaglandins. Kidney Int 27:66-73, 1985.
46. Brandli DW, Sarkissian E, Ng S-C, et al: Individual variability in concentrations of urinary sulindac sulfide. Clin Pharmacol Ther 50:650655, 1991.
47. Duggin GG: Mechanisms in the development of analgesic nephropathy. Kidney Int 18:553-561, 1980.
48. Sabatini S: Analgesic-induced papillary necrosis. Semin Nephrol 8:41-54, 1988.
49. Wortmann DW, Kelsch RC, Kuhns L, et al: Renal papillary necrosis in juvenile rheumatoid arthritis. / Pediatr 97:37-40, 1980.
50. Gokal R, Matthews DR: Renal papillary necrosis after aspirin and alclofenac. BMJ 28:1517-1518, 1977.
51. Shah GM, Muhalwas KK, Winer RL: Renal papillary necrosis due to ibuprofen. Arthritis Rheum 24:1208-1210, 1981.
52. Sandier DP, Burr R, Weinburg CR: Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 115:165172, 1991.
53. Segasothy M, Samad SA, Zulfigar A, et al: Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis 24:17-24, 1994.
54. Nanra RS: Analgesic nephropathy in the 1990's-An Australian perspective. Kidney Int 44(suppl 42):86-92, 1993.
55. Rice D, Turner R, Felts J, et al: Renal failure in patients with rheumatoid arthritis and osteoarthritis on nonsteroidal anti-inflammatory drugs. Fed Proc 43:1100, 1984.
56. Brezin JH, Katz SM, Schwarte AB, et al: Réversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs. N Engl / Med 301:1271-1273, 1979.
57. Abraham PA, Keane WF: Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am / Nephrol 4:1-6, 1984.
58. Levin ML: Patterns of tubulo-interstitial damage associated with nonsteroidal antiinflammatory drugs. Semin Nephrol 8:55-61, 1988.
59. Radford MG, Holley KE, Grande JP, et al: Membranous glomerulopathy associated with the use of nonsteroidal anti-inflammatory drugs. / Am Soc Nephrol 5:359, 1994.
60. Pirson Y, de Strihou CY: Renal side effects of nonsteroidal antiinflammatory drugs. Am /Kidney Dis 8:338-344, 1986.
61. Raftery MJ, Forman P, Farrington K, et al: Fenclofenac induced interstitial nephritis confirmed by inadvertent rechallenge. BMJ 2:81-87, 1985.
62. Reeves WB, Foley RJ, Weinman EJ: Nephrotoxicity from nonsteroidal anti-inflammatory drugs. South Med / 78:318-322, 1985.
63. Shimizu K, Kurosawa T, Maeda T, et al: Free water excretion and washout of renal medullary urea by prostaglandin E. Jpn Heart / 10:437-455, 1969.
64. Ganguli M, Tobian L, Azar S, et al: Evidence that prostaglandin synthesis inhibitors increase the concentration of sodium and chloride in rat renal medulla. Circ fles 40(suppl 1J.-135-139, 1977.
65. Ichikawa I, Brenner BM: Importance of efferent arteriolar vascular tone in regulation of proximal tubule fluid reabsorption and glomerulotubular balance in the rat. / Clin Invest 65:1192-1201, 1980.
66. lino Y, Imai M: Effects of prostaglandins on Na transport in isolated collecting tubules. Pflugers Arch 373:125-132, 1978.
67. Stokes JB, Kokko JP: Inhibition of sodium transport by prostaglandin E2 across the isolated, perfused rabbit collecting tubule. / Clin Invest 59:1099-1104, 1977.
68. Stokes JB: Effect of prostaglandin E2 on chloride transport across the rabbit thick ascending limb of Henle. / Clin Invest 64:495-502,1979.
69. Higashihara E, Stokes JB, Kokko JP, et al: Cortical and papillary micropuncture examination of chloride transport in segments of the rat kidney during inhibition of prostaglandin production. / Clin Invest 64:1277-1287, 1979.
70. Fulgraff G, Meiforth A: Effects of prostaglandin E2 on excretion and reabsorption of sodium and fluid in rat kidneys (micropuncture studies). Pflugers Arch 330:243-256, 1971.
71. +-ATPase activity. Am JPhysiol 256:F570-F576, 1989.
72. Satoh T, Cohen HT, Katz AI: Intracellular signaling in the regulation of renal Na-K-ATPase. J Clin Invest 89:1496-1500,1992.
73. Suva P, Rosen S, Spokes K, et al: Influence of endogenous prostaglandins on mTAL injury. J Am Soc Nephrol 1:808-814, 1990.
74. Stillman IE, Brezis M, Heyman SN, et al: Effects of salt depletion on the kidney: Changes in medullary oxygénation and thick ascending limb size. J Am Soc Nephrol 4:1538-1545, 1994.
75. Schooley RT, Wagley PF, Lietman PS: Edema associated with ibuprofen therapy. JAMA 237:1716-1717, 1977.
76. Brown J, Dollery C, Valdes G: Interaction of nonsteroidal antiinflammatory drugs with antihypertensive and diuretic agents. Am J Med 81(suppl 2B):43-57, 1986.
77. Kirchner KA, Brandon S, Mueller RA, et al: Mechanism of attenuated hydrochlorothiazide response during indomethacin administration. Kidney Int 31:1097-1103, 1987.
78. Nies AS, Gal J, Fadul S, et al: Indomethacin-furosemide interaction: The importance of renal blood flow. J Pharmacol Exp Ther 226:2732, 1983.
79. Greven J, Farjam A: Effect of inhibitors of prostaglandin synthesis on the furosemide action in the loop Henle of rat kidney. Pflugers Arch 411:579-583, 1988.
80. Levenson DJ, Simmons CE, Brenner BM: Arachidonic acid metabolism, prostaglandins and the kidney. Am J Med 72:354-374, 1982.
81. Houston MC: Nonsteroidal anti-inflammatory drugs and antihypertensives. Am / Med 90(suppl 5A):42-47, 1991.
82. Pope JE, Anderson JJ, Felson TD: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153:477-484, 1993.
83. Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? Ann Intern Med 121:289-300, 1994.
84. Mackenzie T, Zawada ET, Johnson MD, et al: The importance of age on prostaglandin E2 excretion in normal and hypertensive men. Nephron 38:178-182, 1984.
85. Minuz P, Barrow SE, Cockcroft }R, et al: Prostacyclin and thromboxane biosynthesis in mild essential hypertension. Hypertension 15:469-474, 1990.
86. Diederich D, Yang Z, Buhler FR, et al: Impaired endotheliumdependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway. Am J Physiol 258:H445-H451, 1990.
87. Henrich WL: Role of prostaglandins in renin secretion. Kidney Int 19:822-830, 1981.
88. Berl T, Henrich WL, Erickson AL, et al: Prostaglandins in the betaadrenergic and baroreceptor-mediated secretion of renin. Am J Physiol 236:F472-F477, 1979.
89. Gerber JG, Nies AS, Olsen RD: Control of canine renin release: Macula densa requires prostaglandin synthesis. J Physiol 319:419-429,1981.
90. Beierwaltes WH, Schryver S, Oison PS, et al: Interaction of the prostaglandin and renin-angiotensin systems in isolated rat glomeruli. Am JPhysiol 239:F602-F608, 1980.
91. Henrich WL, Campbell WB: Relationship between PG and β-adrenergic pathways to renin release in rat renal cortical slices. Am JPhysiol 247.-E343-E348, 1984.
92. Campbell WB, Gomez-Sanchez CE, Adams BV, et al: Attenuation of angiotensin II- and Ill-induced aldosterone release by prostaglandin synthesis inhibitors. / Clin Invest 64:1552-1557, 1979.
93. Pratt JH: Role of angiotensin II in potassium-mediated stimulation of aldosterone secretion in the dog. / Clin Invest 70:667-672, 1982.
94. + channels in cultured rabbit principal cells. Am / Physio! 263:F116-F126, 1992.
95. Nadler JL, Lee FO, Hsueh W, et al: Evidence of prostacyclin deficiency in the syndrome of hyporeninemic hypoaldosteronism. N Eng] / Med 314:1015-1020, 1986.
96. Seelig CB, Maloley PA, Campbell JR: Nephrotoxicity associated with concomitant ACE inhibitor and NSAID therapy. South Med / 83:11441148, 1990.
97. Kramer HJ, Glanzer K, Dusing R: Role of prostaglandins in the regulation of renal water excretion. Kidney Int 19:851-859, 1981.
98. Breyer MD, Jacobson HR, Hebert RL: Cellular mechanisms of prostaglandin E2 and vasopressin interactions in the collecting duct. Kidney Int 38:618-624, 1990.
99. Anderson RJ, Berl T, McDonald KM, et al: Evidence of an n vivo antagonism between vasopressin and prostaglandin in the mammalian kidney. / Clin Invest 56:420-426, 1975.
100. Yared A, Kon V, Ichikawa I: Mechanism of preservation of glomerular perfusion and filtration during acute extracellular fluid volume depletion. / Clin Invest 75:1477-1487, 1985.
101. Perez-Ayuso RM, Arroyo V, Camps J, et al: Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 26:72-80, 1984.
102. Rault RM: Case report: Hyponatremia associated with nonsteroidal antiinflammatory drugs. Am /Med Sei 305:318-320, 1993.
103. Cryer B, Feldman M: Strategies for preventing NSAID-induced ulcers. Drug Therapy 7:25-32, 1994.
104. Physicians' Desk Reference, ed 47. Montvale, NJ, Medical Economics Data, 1994, p 1473.
105. Fries JF, Miller SR, Spitz PW, et al: Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 96:647-655, 1989.
106. Kauffman GL, Reeve JJ, Grossman MI: Gastric bicarbonate secretion: Effect of topical and intravenous 16,16-dimethyl prostaglandin E2. Am / Physio! 239:G44-G48, 1980.
107. McQueen S, Hutton D, Allen A, et al: Gastric and duodenal surface mucus gel thickness in rat: Effects of prostaglandins and damaging agents. Am J Physiol 245:G388-G393, 1983.
108. Gerber JG, Nies AS: Canine gasric mucosal vasodilation with prostaglandins and histamine analogs. Dig Dis Sei 27:870-874, 1982.
109. Levi S, Shaw-Smith C: Non-steroidal anti-inflammatory drugs: How do they damage the gut? Br / Rheumatol 33:605-612, 1994.
110. Gryglewski RJ, Szczeklik A, Wandzilak M: The effect of six prostaglandins, prostacyclin and iloprost on generation of Superoxide anions by human polymorphonuclear leukocytes stimulated by zymosan or formylmethionyl-leucyl-phenylalanine. Acad Pharm 36:42094213, 1987.
111. Kainoh M, Imai R, Umetsu T, et al: Prostacylin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes. Acad Pharm 39:477-484, 1990.
112. Russo PJ, Weidler NW: NSAID-Induced gastroenteropathy: A biochemical dissection. Hosp Pract 12:123-132, 1992.
113. Lockard OO, Ivey KJ, Butt JH, et al: The prevalence of duodenal lesions in patients with rheumatic diseases on chronic aspirin therapy. Gastrointest Endosc 26:5-7, 1980.
114. Lanza F, Umbenhauer E, Nelson R, et al: A double-blind randomized placebo controlled gastroscopic study to compare the effects of indomethacin capsules and indomethacin suppositories on the gastric mucosa of human volunteers. J Rheumato] 9:415-419, 1982.
115. Kimmey MB: NSAID, ulcers, and prostaglandins. J Rheumatol 19:6873, 1992.
116. Cryer B, Goldschmiedt M, Redfern JS, et al: Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins. Gastroenterology 99:1616-1621, 1990.
117. Ligumsky M, Golanska EM, Hansen DG, et al: Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in rat. Gastroenterology 84:756-761, 1983.
118. Baskin WN, Ivey KJ, Krause WJ, et al: Aspirin-induced ultrastructural changes in human gastric mucosa. Ann Intern Med 85:299-303,1976.
119. Whittle BJR, Higgs GA, Eakins KE, et al: Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 284:271-273, 1980.
120. Rainsford KD, Willis C: Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production. Dig Dis Sei 27:624-635, 1982.
121. Whittle BJR: Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 80:94-98, 1981.
122. Redfern JS, Lee E, Feldman M: Effect of indomethacin on gastric mucosal prostaglandins in humans. Gastroenterology 92:969-977, 1987.
123. Levine RA, Petokas S, Nandi J, et al: Effects of nonsteroidal, antiinflammatory drugs on gastrointestinal injury and prostanoid generation in healthy volunteers. Dig Dis Sei 33:660-666, 1988.
124. Feldman M: Can gastroduodenal ulcers in NSAID users be prevented? Ann Intern Med 119:337-339, 1993.
125. Graham DY, Agrawal MM, Roth SH: Prevention of NSAID-induced gastric ulcer with misoprostol: Multicentre, double-blind, placebocontrolled trial. Lancet 2:1277-1280, 1988.
126. Ensanullah RSB, Page MC, Tildesley G, et al: Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine. BMJ 297:1017-1021, 1988.
127. Robinson MG, Griffin JW, Bowers J, et al: Effect of ranitidine gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sei 34:424-428, 1989.
128. Graham DY, White RH, Moreland LW, et al: Duodenal and gastric ulcer prevention with misoprostol in arthritis taking NSAIDs. Ann Intern Med 119:257-262, 1993.
129. Soll AH, Weinstein WM, Kurata J, et al: Nonsteroidal antiinflammatory drugs and peptic ulcer disease. Ann Intern Med 114:307-319, 1991.
130. Graham DY, Smith JL, Dobbs SM: Gastric adaptation occurs with aspirin administration in man. Dig Dis Sei 28:1-6, 1983.
131. Metzger WH, McAdam L, Bluestone R, et al: Acute gastric mucosal injury during continuous or interrupted aspirin ingestion in humans. Dig Dis Sei 21:963-968, 1976.
132. O'Laughlin JC, Hoftiezer JW, Ivey KJ: Effect of aspirin on the human stomach in normals: Endoscopie comparison of damage produced one hour, 24 hours, and 2 weeks after administration. Scand / Gastroenterol 16(suppl 67):211-214, 1981.
133. Laine L, Weinstein WM: Subepithelial hemorrhages and erosions of human stomach. Dig Dis Sei 33:490-503, 1988.
134. Graham DY, Lidsky MD, Cox AM, et al: Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection. Gastroenterology 100:1653-1657, 1991.
135. Sontag S, Graham DY, Belsito A, et al: Cimetidine, cigarette smoking, and recurrence of duodenal ulcers. N Engl / Med 311:689-693, 1984.
136. Van Deventer GM, Elashoff JD, Reedy TJ, et al: A randomized study of maintenance therapy with ranitidine to prevent the recurrence of duodenal ulcer. N Engl / Med 320:1113-1119, 1989.
137. Hentschel E, Brandstatter G, Dragosics B, et al: Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N EngJ / Med 328:308- 312, 1993.
138. Armstrong CP, Blower AL: Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulcération. Gut 28:527-532, 1987.
139. Meilern H, Stave R, Myren J, et al: Symptoms in patients with peptic ulcer and hematemesis and/or melena related to the use of nonsteroidal anti-inflammatory drugs. Scand J Gastroenterol 20:1246-1248, 1985.
140. Skander MP, Ryan FP: Non-steroidal anti-inflammatory drugs and pain free peptic ulcération in the elderly. BMJ 297:833-834, 1988.
141. Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs. Ann Intern Med 115:787-796, 1991.
142. Carson JL, Willett LR: Toxicity of nonsteroidal anti-inflammatory drugs. Drugs 46(suppl l):243-248, 1993.
143. Piper JM, Ray WA, Daugherty JR, et al: Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 114:735-740, 1991.
144. Kurata JH, Abbey DE: The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol 12:260-266, 1990.
145. Holvoet J, Terriere L, Van Hee W, et al: Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: A case-control study. Gut 32:730-734, 1991.
146. Carson JL, Strom BL, Soper KA, et al: The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med 147:85-88, 1987.
147. Laine L, Peterson WL: Bleeding peptic ulcer. N Engl J Med 331:717728, 1994.
148. Griffin MR, Piper JM, Daugherty JR, et al: Nonsteroidal antiinflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 114:257-263, 1991.
149. Lee M, Cryer B, Feldman M: Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med 120:184-189, 1994.
150. Agrawal NM, Roth S, Graham DY, et al: Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory druginduced gastric ulcer. Ann Intern Med 115:195-200, 1991.
151. Davies GR, Wilkie ME, Rampton DS: Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig Dis Sei 38:417-425, 1993.
152. Allison MC, Howatson AL, Torrance CJ, et al: Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Eng] J Med 327:749-754, 1992.
153. Wallace JL: Prostaglandins, NSAIDs, and cytoprotection. Gastroenterol Clin North Am 21:631-641, 1992.